AETHLON MEDICAL INC
For the period ended Jun 26, 2025. Filed Jun 27, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 26, 2025 · Filed Jun 27, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Earnings Script
Earnings Script
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID
Conference Call to be Held Today at 4:30 p.m. ET
SAN DIEGO, June 26, 2025 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.